Title:
PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG
Document Type and Number:
WIPO Patent Application WO/2021/187922
Kind Code:
A1
Abstract:
The present invention provides a pharmaceutical composition for cancer treatment comprising a fusion protein including an IL-2 protein and a CD80 protein and an anticancer drug as active ingredients. A fusion protein including a CD80 fragment, immunoglobulin Fc, and an IL-2 variant, which is one embodiment of the present invention, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer drug is administered in combination with the fusion protein, cancer can be effectively suppressed. Accordingly, the pharmaceutical composition comprising the fusion protein including the IL-2 protein and the CD80 protein and the anticancer drug as active ingredients increases immune activity in the body and thus can be effectively used not only for cancer but also for infectious diseases, and is highly industrially applicable.
Inventors:
JANG MYOUNG HO (KR)
NAM SU YOUN (KR)
KOH YOUNG JUN (KR)
HA DAN BEE (KR)
KIM MYUNG HEE (KR)
NAM SU YOUN (KR)
KOH YOUNG JUN (KR)
HA DAN BEE (KR)
KIM MYUNG HEE (KR)
Application Number:
PCT/KR2021/003375
Publication Date:
September 23, 2021
Filing Date:
March 18, 2021
Export Citation:
Assignee:
GI INNOVATION INC (KR)
International Classes:
A61K38/00; A61K38/17; A61K38/20; A61K45/06; A61P35/00; C07K14/55; C07K14/705
Domestic Patent References:
| WO2018237158A1 | 2018-12-27 |
Foreign References:
| KR102058846B1 | 2020-02-20 | |||
| JP2016540042A | 2016-12-22 | |||
| KR102201086B1 | 2021-01-11 | |||
| KR20180030580A | 2018-03-23 | |||
| US5229109A | 1993-07-20 | |||
| KR101667096B1 | 2016-10-18 |
Other References:
PARK J. C., K.H. PYO, Y.J. SONG, W.J. LEE, J. KIM, H.N. JI, S.S. PARK, Y.J. KOH, K. LEE, B. CHO, B.-H. CHUN, Y.M. OH, B.-G. YANG, : "GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumour effects in preclinical models", ANNALS OF ONCOLOGY, vol. 30, no. S5, 30 September 2019 (2019-09-30), pages 1 - 1, XP055813776, DOI: 10.1093/annonc/mdz253.049
CHAN L , HARDWICK N , DARLING D , GALEA-LAURI J , GAKEN, J , DEVEREUX S, KEMENY M , MUFTI, G , FARZANEH, F: "IL-2/B7.1 (CD80) Fusagene Transduction of AML Blasts by a Self-Inactivating Lentiviral Vector Stimulates T Cell Responses in Vitro: a Strategy to Generate Whole Cell Vaccines for AML", MOLECULAR THERAPY, vol. 11, no. 1, 1 January 2005 (2005-01-01), US, pages 120 - 131, XP004672534, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2004.09.006
See also references of EP 4140495A4
CHAN L , HARDWICK N , DARLING D , GALEA-LAURI J , GAKEN, J , DEVEREUX S, KEMENY M , MUFTI, G , FARZANEH, F: "IL-2/B7.1 (CD80) Fusagene Transduction of AML Blasts by a Self-Inactivating Lentiviral Vector Stimulates T Cell Responses in Vitro: a Strategy to Generate Whole Cell Vaccines for AML", MOLECULAR THERAPY, vol. 11, no. 1, 1 January 2005 (2005-01-01), US, pages 120 - 131, XP004672534, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2004.09.006
See also references of EP 4140495A4
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF:
Previous Patent: ELECTRODE ASSEMBLY
Next Patent: ORGANOELECTROLUMINESCENT DEVICE USING POLYCYCLIC AROMATIC DERIVATIVE COMPOUNDS
Next Patent: ORGANOELECTROLUMINESCENT DEVICE USING POLYCYCLIC AROMATIC DERIVATIVE COMPOUNDS